Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 17.11% is in line with its 4-year average of 18.72%, near the low end of its 4-year range (14.70%–56.55%).
1.25% above its 12-month average of 16.90%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 20.52%.
GROSS MARGIN
17.11%
GROSS MARGIN AVG TTM
16.90%
GROSS MARGIN AVG 3Y
18.43%
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+1.25%
CURRENT VS 3Y AVG
-7.16%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
58.60%
median of 100 covered companies
CURRENT VS SECTOR MEDIAN
-70.80%
vs the sector median at left
Fortrea Holdings Inc.
Market Cap
$1.90B
Gross Margin
17.11%
TTM Avg
16.90%
3Y Avg
18.43%
5Y Avg
N/A
Market Cap
$1.74B
Gross Margin
49.52%
TTM Avg
50.81%
3Y Avg
52.12%
5Y Avg
52.25%
Market Cap
$1.71B
Gross Margin
76.47%
TTM Avg
79.35%
3Y Avg
79.86%
5Y Avg
39.87%
Market Cap
$2.16B
Gross Margin
-61.96%
TTM Avg
-19.42%
3Y Avg
-14.39%
5Y Avg
23.74%
Market Cap
$2.52B
Gross Margin
84.05%
TTM Avg
-197.31%
3Y Avg
-176.53%
5Y Avg
-71811.06%
Market Cap
$2.76B
Gross Margin
58.69%
TTM Avg
59.64%
3Y Avg
63.22%
5Y Avg
64.62%
Market Cap
$1.00B
Gross Margin
73.53%
TTM Avg
70.13%
3Y Avg
70.04%
5Y Avg
68.74%
Market Cap
$474.59M
Gross Margin
42.92%
TTM Avg
41.39%
3Y Avg
40.24%
5Y Avg
40.24%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fortrea Holdings Inc. (FTRE) | $1.90B | 17.11% | 16.90% | 18.43% | N/A |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.74B | 49.52% | 50.81% | 52.12% | 52.25% |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.71B | 76.47% | 79.35% | 79.86% | 39.87% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.16B | -61.96% | -19.42% | -14.39% | 23.74% |
| Beam Therapeutics Inc. (BEAM)vs › | $2.52B | 84.05% | -197.31% | -176.53% | -71811.06% |
| TransMedics Group, Inc. (TMDX)vs › | $2.76B | 58.69% | 59.64% | 63.22% | 64.62% |
| Teladoc Health, Inc. (TDOC)vs › | $1.00B | 73.53% | 70.13% | 70.04% | 68.74% |
| NeoGenomics, Inc. (NEO)vs › | $474.59M | 42.92% | 41.39% | 40.24% | 40.24% |
| NRC Health (NRC)vs › | $458.62M | 56.33% | 58.27% | 60.30% | 61.48% |
| Shoulder Innovations, Inc. (SI)vs › | $394.23M | 77.34% | 76.74% | 77.57% | 77.57% |
Gross Margin
17.1%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 20.52% |
| 2026-03-31 | 16.31% |
| 2025-12-31 | 16.93% |
| 2025-09-30 | 14.70% |
| 2025-06-30 | 16.04% |
| 2025-03-31 | 17.89% |
| 2024-12-31 | 20.22% |
| 2024-09-30 | 21.97% |
| 2024-06-30 | 20.70% |
| 2024-03-31 | 16.30% |
| 2023-12-31 | 15.44% |
| 2023-09-30 | 21.01% |
| 2023-06-30 | 21.57% |
| 2023-03-31 | 21.96% |
| 2022-12-31 | 56.55% |
| 2022-09-30 | 21.97% |
| 2022-06-30 | 19.59% |
| 2022-03-31 | 15.06% |
